公开(公告)号：US20230365618A1

公开(公告)日：2023-11-16

申请号：US18028460

申请日：2021-10-11

申请人： Durect Corporation

发明人： ANDREW R. MIKSZTAL ,  WEIQI LIN ,  MICHAEL HOLTZ-MULHOLLAND ,  JULIETTE SABBATANI ,  TRAVIS LEE HOUSTON ,  STEPHAN D. PARENT

IPC分类号： C07J31/00

CPC分类号： C07J31/00 ,  C07B2200/13

摘要： Crystalline forms of thiocholesterol are disclosed herein. Such forms include crystalline Form thiocholesterol, crystalline Form B thiocholesterol, crystalline thiocholesterol Form C. Processes for making crystalline thiocholesterol, pharmaceutical compositions comprising crystalline thiocholesterol, methods of treatment comprising administering crystalline thiocholesterol, including ctystalline thiocholesterol Form A, crystalline thiocholesterol Form B, and/or crystalline thiocholesterol Form C are further provided.

公开(公告)号：US20220273518A1

公开(公告)日：2022-09-01

申请号：US17581665

申请日：2022-01-21

申请人： DURECT CORPORATION

发明人： ANDREW R. MIKSZTAL ,  JUDY JOICE ,  SUSAN AUTIO ,  MARK P. DAVIS

IPC分类号： A61J1/20 ,  A61K31/445 ,  A61K47/10 ,  A61K47/26

摘要： The present disclosure relates to sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises N-oxide of active pharmaceutical agent at a level less than 1 wt %, based on weight of the composition. In some case, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

公开(公告)号：US20240115463A1

公开(公告)日：2024-04-11

申请号：US18235256

申请日：2023-08-17

申请人： Durect Corporation

发明人： ANDREW R. MIKSZTAL ,  JUDY JOICE ,  SUSAN AUTIO ,  MARK P. DAVIS

IPC分类号： A61J1/20 ,  A61K31/445 ,  A61K47/10 ,  A61K47/26

CPC分类号： A61J1/2089 ,  A61K31/445 ,  A61K47/10 ,  A61K47/26

摘要： The present disclosure relates to sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises N-oxide of active pharmaceutical agent at a level less than 1 wt %, based on weight of the composition. In some case, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

公开(公告)号：US20220133595A1

公开(公告)日：2022-05-05

申请号：US17504913

申请日：2021-10-19

申请人： DURECT CORPORATION

发明人： ANDREW R. MIKSZTAL ,  JUDY JOICE ,  SUSAN AUTIO ,  MARK P. DAVIS

IPC分类号： A61J1/20 ,  A61K31/445 ,  A61K47/26 ,  A61K47/10

摘要： The present disclosure relates to sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises N-oxide of active pharmaceutical agent at a level less than 1 wt %, based on weight of the composition. In some case, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.

公开(公告)号：US20230056273A1

公开(公告)日：2023-02-23

申请号：US17783248

申请日：2020-12-23

申请人： Durect Corporation

发明人： ANDREW R. MIKSZTAL ,  SHAWN JOHNSTONE ,  MICHAEL HOLTZ-MULHOLLAND ,  FLAVIO LOPEZ ,  HOWARD SARD ,  JIE LI ,  MARIO GONZALEZ ,  STEPHAN D. PARENT ,  TRAVIS LEE HOUSTON ,  ROBERT WENSLOW

IPC分类号： C07J31/00

摘要： Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided

公开(公告)号：US20220273633A1

公开(公告)日：2022-09-01

申请号：US17744509

申请日：2022-05-13

申请人： Durect Corporation

发明人： ADRIAN NEIL VERITY ,  STEVEN HALLADAY ,  VAELING MILLER ,  PETER LANGECKER ,  DMITRI LISSIN ,  ANDREW R. MIKSZTAL ,  JUDY JOICE ,  SUSAN AUTIO ,  MARK P. DAVIS

IPC分类号： A61K31/445 ,  A61K9/00 ,  A61P23/02

摘要： The present disclosure provides for methods of producing analgesia in a subject. In some cases, methods produce analgesia in a subject undergoing arthroscopic subacromial decompression surgery. The present disclosure also relates to improved sustained release drug delivery systems. In some cases, a composition comprises an active pharmaceutical agent; at least one of sucrose acetate isobutyrate and a polyorthoester; an organic solvent; and 2,6-dimethylaniline, wherein the 2,6-dimethylaniline is present at a level less than 500 ppm. In some cases, a composition comprises bupivacaine N-oxide at a level less than 1 wt %, based on weight of the composition. In some cases, a composition comprises metal present at a level less than 5 ppm. Dosage forms and methods are also provided.